Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells

Oncology Letters

Volumn 8, Issue 6, 2014, Pages 2709-2714

  Ninomiya, Itasu ^a   Yamazaki, Keisuke ^a   Oyama, Katsunobu ^a   Hayashi, Hironori ^a   Tajima, Hidehiro ^a   Kitagawa, Hirohisa ^a   Fushida, Sachio ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Differentiation; Lung metastasis; Lymph node metastasis; Pancreatic cancer; Pioglitazone; Rectal xenograft model

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; INTERLEUKIN 8; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 84908043199     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2553     Document Type: Article

References (48)

1. Matsuno S, Egawa S, Fukuyama S, et al: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 28: 219-230, 2004.
2. Schmidt CM, Powell ES, Yiannoutsos CT, et al: Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 139: 718-727, 2004.
3. Höhne MW, Halatsch ME, Kahl GF and Weinel RJ: Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res 52: 2616-2619, 1992.
4. Govindarajan R, Ratnasinghe L, Simmons DL, et al: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25: 1476-1481, 2007.
5. Choudhary R, Li H, Winn RA, et al: Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia 12: 224-234, 2010.
6. Keshamouni VG, Reddy RC, Arenberg DA, et al: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108, 2004.
7. Reddy RC, Srirangam A, Reddy K, et al: Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer. Neoplasia 10: 597-603, 2008.
8. Lyon CM, Klinge DM, Do KC, et al: Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30: 2095-2099, 2009.
9. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Inv 106: 467-472, 2000.
10. Braissant O, Foufelle F, Scotto C, Dauça M and Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354-366, 1996.
11. Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
12. Tontonoz P, Singer S, Forman BM, et al: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94: 237-241, 1997.
13. Mueller E, Sarraf P, Tontonoz P, et al: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1: 465-470, 1998.
14. Elstner E, Müller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
15. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998.
16. Brockman JA, Gupta RA and Dubois RN: Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115: 1049-1055, 1998.
17. Kitamura S, Miyazaki Y, Shinomura Y, et al: Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 90: 75-80, 1999.
18. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998.
19. Takahashi N, Okumura T, Motomura W, et al: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 455: 135-139, 1999.
20. Elnemr A, Ohta T, Iwata K, et al: PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 17: 1157-1164, 2000.
21. Itami A, Watanabe G, Shimada Y, et al: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer 94: 370-376, 2001.
22. Galli A, Ceni E, Crabb DW, et al: Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut 53: 1688-1697, 2004.
23. Pignatelli M, Cortés-Canteli M, Lai C, Santos A and Perez-Castillo A: The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J Cell Sci 114: 4117-4126, 2001.
24. Yoshizumi T, Ohta T, Ninomiya I, et al: Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
25. Panigrahy D, Singer S, Shen LQ, et al: PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932, 2002.
26. Takano S, Kubota T, Nishibori H, et al: Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 28: 3593-3599, 2008.
27. Ninomiya I, Terada I, Yoshizumi T, et al: Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Int J Cancer 112: 135-142, 2004.
28. Kip1 in Human Pancreatic Carcinoma Cells. Cancer Res 60: 5558-5564, 2000.
29. Kawa S, Nikaido T, Unno H, et al: Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24: 1-7, 2002.
30. Allum WH, Stokes HJ, Macdonald F and Fielding JW: Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry. J Clin Pathol 39: 610-614, 1986.
31. Blin N and Stafford DW: A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3: 2303-2308, 1976.
32. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
33. Kuwada Y, Sasaki T, Morinaka K, et al: Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 22: 765-771, 2003.
34. Shi Q, Abbruzzese JL, Huang S, et al: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5: 3711-3721, 1999.
35. Le X, Shi Q, Wang B, et al: Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20: 935-946, 2000.
36. Koch AE, Polverini PJ, Kunkel SL, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801, 1992.
37. Wolfe MM, Lichtenstein DR and Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899, 1999.
38. Masferrer JL, Seibert K, Zweifel B and Needleman P: Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 89: 3917-3921, 1992.
39. Kujubu DA, Fletcher BS, Varnum BC, Lim RW and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872, 1991.
40. Masferrer JL, Leahy KM, Koki AT, et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
41. Ninomiya I, Nagai N, Oyama K, et al: Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep 28: 777-784, 2012.
42. Seshasai SR, Kaptoge S, Thompson A, et al; Emerging Risk Factors Collaboration: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364: 829-841, 2011.
43. Singh S, Singh PP, Singh AG, et al: Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 108: 510-519, 2013.
44. Cohen SM: Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 87: 322-327, 2005.
45. Tannehill-Gregg SH, Sanderson TP, Minnema D, et al: Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci 98: 258-270, 2007.
46. Lewis JD, Ferrara A, Peng T, et al: Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34: 916-922, 2011.
47. Ferrara A, Lewis JD, Quesenberry CP Jr, et al: Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 34: 923-929, 2011.
48. Zhu Z, Shen Z, Lu Y, Zhong S and Xu C: Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 98: 159-163, 2012.